Press Releases 2020 - Emerald Health Pharmaceuticals

Loading...

Press Releases

Press Releases 2020Angelita Garcia2020-02-18T17:33:30-08:00

2020

Dec 3, 2020

Emerald Health Pharmaceuticals to Open a New Financing Round Under its Regulation A+ Offering

Oct 19, 2020

Announcement of Closing Date for Current Regulation A+ Offering Round

Jul 27, 2020

Emerald Health Pharmaceuticals Begins Enrollment in Phase 2a Study of EHP-101 for the Treatment of Systemic Sclerosis

Jul 20, 2020

Emerald Health Pharmaceuticals Renews Regulation A Offering and Provides Mid-Year Corporate Update

May 28, 2020

Emerald Health Pharmaceuticals Provides Phase 2 Systemic Sclerosis Clinical Trial Update

Mar 31, 2020

Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study in Systemic Sclerosis

Mar 23, 2020

Emerald Health Pharmaceuticals’ Lead Product Candidate Determined Not to be a Controlled Substance in Canada

Mar 16, 2020

Emerald Health Pharmaceuticals Expands Global Technology Protection with the Granting of Six New International Patents

Mar 3, 2020

Emerald Health Pharmaceuticals Receives Fast Track Designation from US FDA for EHP-101 in the Treatment of Systemic Sclerosis

Feb 27, 2020

Emerald Health Pharmaceuticals Presents Phase I Clinical Data and Preclinical Remyelination Data at ACTRIMS 2020 Conference

Feb 19, 2020

Emerald Health Pharmaceuticals to Present at 2020 ACTRIMS Conference on Multiple Sclerosis

Jan 29, 2020

Emerald Health Pharmaceuticals Granted Orphan Designation in Europe for Huntington’s Disease

Jan 13, 2020

Emerald Health Pharmaceuticals Receives U.S. FDA Clearance of IND Application for Phase 2 Study of EHP-101 in Orphan Disease